The subcutaneous therapy is CagriSema, a fixed dose combination of cagrilintide and semaglutide. In a phase 3 trial spanning 68 weeks, Novo Nordisk tested the drug’s efficacy compared to a placebo. The trial included 1,206 people who have a mean baseline body weight of about 225 pounds, are obese or overweight and have Type 2 diabetes.
If all adhered to the weekly treatment, CagriSema patients achieved 15.7% weight loss, compared to 3.1% with the placebo. Nearly 90% of CagriSema patients achieved a weight loss of 5% or more after 68 weeks, while the same result was logged by 30.3% of the placebo group.
Regardless of medication adherence, weight loss results were 13.7% with CagriSema and 3.4% with the placebo.
Although the trial results failed to meet Novo Nordisk’s projection of 25% weight loss, the Denmark-based drugmaker said it plans to seek regulatory approval of CagriSema in early 2026.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.